Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Olema Pharmaceuticals (OLMA) Cash & Equivalents (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Cash & Equivalents data on record, last reported at $52.5 million in Q1 2026.

  • On a quarterly basis, Cash & Equivalents rose 3.77% to $52.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $52.5 million, a 3.77% increase, with the full-year FY2025 number at $48.3 million, down 65.37% from a year prior.
  • Cash & Equivalents reached $52.5 million in Q1 2026 per OLMA's latest filing, up from $48.3 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for OLMA hit a ceiling of $139.5 million in Q4 2024 and a floor of $16.9 million in Q2 2024.
  • A 5-year average of $48.4 million and a median of $35.9 million in 2024 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: surged 338.02% in 2023, then tumbled 69.43% in 2024.
  • Tracing OLMA's Cash & Equivalents over 5 years: stood at $23.7 million in 2022, then soared by 189.17% to $68.5 million in 2023, then soared by 103.5% to $139.5 million in 2024, then plummeted by 65.37% to $48.3 million in 2025, then rose by 8.79% to $52.5 million in 2026.
  • Business Quant data shows Cash & Equivalents for OLMA at $52.5 million in Q1 2026, $48.3 million in Q4 2025, and $35.3 million in Q3 2025.